(1995; 152 pages) [French] [Spanish]
Group: anthelminthic agent
Chewable tablet 200 mg, 400 mg
A benzimidazole derivative that interferes with microtubule assembly and blocks glucose uptake by many intestinal and tissue nematodes and some cestodes.
It is poorly absorbed from the gastrointestinal tract and is rapidly and extensively metabolized in the liver. The absorbed fraction, which has a plasma half-life of some 8 hours, is largely eliminated in the urine as the sulfoxide.
Treatment of ascariasis, hookworm infections, strongyloidiasis, enterobiasis, trichuriasis, trichostrongyliasis and capillariasis.
Dosage and administration
Adults and children over 2 years: a single dose of 400 mg is sufficient to eliminate most cases of ascariasis, hookworm infection, enterobiasis, trichostrongyliasis, capillariasis and moderate T. trichiura infections.
Strongyloidiasis and heavy T. trichiura infections require a 3-day course of treatment.
• Known hypersensitivity.
• Early pregnancy.
Use in pregnancy
Albendazole has been shown to have teratogenic and embryotoxic potential in rats and rabbits. Although high priority should be accorded to the treatment of pregnant women, albendazole should not be administered during the first trimester.
Transient gastrointestinal discomfort and headache have occasionally been reported.
Emesis or gastric lavage may be of value if undertaken within a few hours of ingestion. Otherwise treatment is symptomatic and supportive. No specific antidote exists.
Tablets should be stored in well-closed containers.